Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 10 April 2025, 12:57 HKT/SGT
Share:
Hebe Biotechnology Appoints Industry Insider Dr. Hannes Hentze as Chief Development Officer to Advance Next-Generation GLP-1 RA Weight Loss Therapy

SINGAPORE, Apr 10, 2025 - (ACN Newswire) - April 9, Hebe Biotechnology Pte Ltd (“Hebe Bio”), a Singapore-based innovator in metabolic health therapeutics, today announced the appointment of Hannes Hentze, PhD, MBA as Chief Development Officer (CDO), effective April 1, 2025. Dr. Hentze will lead the global development strategy for the company’s next-generation GLP-1 receptor agonist (GLP-1 RA), a cutting-edge weight loss therapy designed to enhance efficacy and tolerability, addressing the global obesity challenge.

Strategic Leadership for a Transformative Therapy

Dr. Hentze brings over two decades of experience in pharmaceutical development, specializing in oncology, metabolic disorders, and biologics. His background spans academic research (IMCB, NTU), biotech ventures (S*BIO, ES Cell International, ASLAN), and large pharmaceutical players (Schering-Plough, MSD). Most recently, he served as Associate Director of Translational Sciences at EDDC (A*STAR).

At Hebe Bio, Dr. Hentze will spearhead preclinical and translational development, guiding clinical trial readiness, regulatory strategy, and strategic partnerships to accelerate the GLP-1 RA program’s global commercialization.

Sam Lim, MD, PhD, MBA, CEO of Hebe Bio, remarked, “We are thrilled to welcome Hannes to our leadership team. His deep expertise in metabolic drug development and his visionary approach align perfectly with our mission to deliver transformative therapies. His leadership will be pivotal as we accelerate our GLP-1 RA candidate, which has the potential to redefine standards in weight management and healthspan extension.”

Advancing Innovation in Metabolic Health

Hebe Bio’s GLP-1 RA therapy integrates cutting-edge science to optimize fat loss in the context of maintaining muscle mass, while minimizing common side effects associated with existing therapies. Preclinical data on Hebe Bio’s lead molecules have demonstrated superior efficacy and tolerability, positioning it as a next-generation solution for truly sustainable, healthspan-extending weight loss therapy.

Dr. Hentze expressed enthusiasm about his new role at Hebe Bio: “Joining Hebe Bio is a unique opportunity to make a real impact in a critical area of global health. Our GLP-1 RA candidate has the potential to shift the obesity treatment paradigm, and I look forward to collaborating with the exceptional Hebe Bio team, and our global partners to bring this therapy to patients worldwide.”

About Hebe Biotechnology Pte Ltd

Hebe Biotechnology is a Singapore-headquartered biopharmaceutical company dedicated to pioneering next-generation therapies for metabolic and chronic diseases. By combining advanced research with strategic global partnerships, Hebe Bio is committed to delivering patient-centric solutions that address unmet medical needs.

Media Contact:

Ms Kung
Bright International Communications Limited
Email: ir@brightcommns.com
Mobile: +852 4637 1627
Website: www.hebebio.sg




Topic: Press release summary Sectors: BioTech, Startups
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind  
May 30, 2025 19:00 HKT/SGT
Mitsubishi Corporation Establishes New Corporate Venture Capital Company  
Friday, May 30, 2025 5:36:00 PM
The PropertyGuru Asia Property Awards (Middle East) return for 2025 edition with inaugural Dubai launch  
May 30, 2025 14:00 HKT/SGT
Honda to Co-develop Refueling Port Connecting System for On-orbit Satellite Refueling with Astroscale  
Friday, May 30, 2025 10:54:00 AM
IFS and NEC Strengthen their Strategic Partnership to Create New Value  
Friday, May 30, 2025 9:11:00 AM
Genetec maintains profitability in Q3FY2025 on higher revenue  
May 29, 2025 20:00 HKT/SGT
Naoris Protocol Raises $3M in Strategic Round Led by Mason Labs  
May 29, 2025 19:00 HKT/SGT
MODONG Coffee Proudly Sponsors "G-DRAGON 2025 WORLD TOUR [Ubermensch] IN TAIPEI, presented by KGI FINANCIAL GROUP" as Official Sponsor  
May 29, 2025 18:19 HKT/SGT
Mazda Production and Sales Results for April 2025  
Thursday, May 29, 2025 5:44:00 PM
Euro Manganese Closes C$11.2 million (A$12.3 million) Financing  
May 29, 2025 16:09 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: